Tags

Type your tag names separated by a space and hit enter

Drug therapy of reflux oesophagitis: an update.
Scand J Gastroenterol Suppl 1989; 168:38-49SJ

Abstract

The various therapeutic approaches for reflux oesophagitis are to enhance oesophageal clearance, to coat damaged tissue, to increase the competence of the reflux barrier, to reduce the volume and pH of gastric contents, and to improve gastric emptying and pyloric sphincter competence. Unfortunately, drug therapy of reflux oesophagitis is not yet ideal. Of the prokinetic agents, cisapride is the only drug with proven benefit. Single-agent therapy with the H2-receptor antagonists or sucralfate results in similar degrees of symptom relief and healing. Rapid symptom relief and healing are achieved by omeprazole; however, the significance of sustained achlorhydria remains to be established. Dinnertime dosing of cimetidine appears to be a rational method of suppressing late-evening gastric acidity. Patients with severe or recalcitrant disease should not be treated with conventional therapy alone; the results of controlled studies of combination therapy with the H2-receptor antagonists and sucralfate or cisapride will be viewed with interest.

Authors+Show Affiliations

Gastroenterology Dept. University of Amsterdam, Academic Medical Center, The Netherlands.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2575792

Citation

Tytgat, G N.. "Drug Therapy of Reflux Oesophagitis: an Update." Scandinavian Journal of Gastroenterology. Supplement, vol. 168, 1989, pp. 38-49.
Tytgat GN. Drug therapy of reflux oesophagitis: an update. Scand J Gastroenterol Suppl. 1989;168:38-49.
Tytgat, G. N. (1989). Drug therapy of reflux oesophagitis: an update. Scandinavian Journal of Gastroenterology. Supplement, 168, pp. 38-49.
Tytgat GN. Drug Therapy of Reflux Oesophagitis: an Update. Scand J Gastroenterol Suppl. 1989;168:38-49. PubMed PMID: 2575792.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug therapy of reflux oesophagitis: an update. A1 - Tytgat,G N, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 38 EP - 49 JF - Scandinavian journal of gastroenterology. Supplement JO - Scand. J. Gastroenterol. Suppl. VL - 168 N2 - The various therapeutic approaches for reflux oesophagitis are to enhance oesophageal clearance, to coat damaged tissue, to increase the competence of the reflux barrier, to reduce the volume and pH of gastric contents, and to improve gastric emptying and pyloric sphincter competence. Unfortunately, drug therapy of reflux oesophagitis is not yet ideal. Of the prokinetic agents, cisapride is the only drug with proven benefit. Single-agent therapy with the H2-receptor antagonists or sucralfate results in similar degrees of symptom relief and healing. Rapid symptom relief and healing are achieved by omeprazole; however, the significance of sustained achlorhydria remains to be established. Dinnertime dosing of cimetidine appears to be a rational method of suppressing late-evening gastric acidity. Patients with severe or recalcitrant disease should not be treated with conventional therapy alone; the results of controlled studies of combination therapy with the H2-receptor antagonists and sucralfate or cisapride will be viewed with interest. SN - 0085-5928 UR - https://www.unboundmedicine.com/medline/citation/2575792/Drug_therapy_of_reflux_oesophagitis:_an_update_ L2 - https://www.lens.org/lens/search?q=citation_id:2575792 DB - PRIME DP - Unbound Medicine ER -